Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Stefan J. Müller, Dipl.-Pharm., Anna Simon, Sarah Decker, PhD, Marie Follo, PhD, Justus Duyster, MD PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2774.

https://doi.org/10.1182/blood.V128.22.2774.2774

Published: 2016

Journal Articles

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, MD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, Hermann Einsele, MD, Monika Engelhardt, MD PhD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Jan Endell, PhD, Rainer Boxhammer, PhD, Christian Peschel, MD

Blood (2016) 128 (22): 1152.

https://doi.org/10.1182/blood.V128.22.1152.1152

Published: 2016

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Giulia Graziani, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Georg W. Herget, MD PhD, Karl Henne, MD, Annette M. May, Justus Duyster, MD, Werner Vach, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 5979.

https://doi.org/10.1182/blood.V128.22.5979.5979

Published: 2016

Journal Articles

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Stefan J. Müller, Dipl.-Pharm., Johannes M. Waldschmidt, MD, Johanna Senger, PhD, Dagmar Wider, Andreas R. Thomsen, MD, Gabriele Ihorst, PhD, Justus Duyster, MD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2109.

https://doi.org/10.1182/blood.V128.22.2109.2109

Published: 2016

Journal Articles

The APC/C Coactivator Cdh1 Controls Self-Renewal and Differentiation of Human and Murine HSPCs

Daniel Ewerth, Stefanie Kreutmair, Andrea Schmidts, Marie Follo, PhD, Dagmar Wider, Julia B. Schueler, DVM, PhD, Julia Felthaus, Justus Duyster, MD, Anna Lena Illert, MD, Monika Engelhardt, MD PhD, Wäsch Ralph, MD

Blood (2016) 128 (22): 2650.

https://doi.org/10.1182/blood.V128.22.2650.2650

Published: 2016

Journal Articles

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Alexander Zober, MD, Mandy Möller, Sandra-Maria Dold, Gabriele Ihorst, PhD, Stefanie Hieke, PhD, Jochen Knaus, Milena Pantic, PhD, Barbara Deschler-Baier, MD, Stefan Knop, Hermann Einsele, Christian Langer, Lars-Olof Muegge, MD, Wolfram Poenisch, MD, Justus Duyster, MD PhD, Martin Schumacher, PhD, Ralph M. Waesch, MD PhD, Monika Engelhardt, MD PhD

Blood (2015) 126 (23): 5616.

https://doi.org/10.1182/blood.V126.23.5616.5616

Published: 2015

Journal Articles

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Alexander Keller, MD, Johannes M. Waldschmidt, MD, Dagmar Wider, Dorothee Jakobs, Mandy Möller, Heike Reinhardt, Milena Pantic, PhD, Olga Grishina, MD, Gabriele Ihorst, PhD, Annette M May, MD, Anna Frey, MD, Ulrike Kohlweyer, PhD, Justus Duyster, MD PhD, Manfred Jung, PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 4260.

https://doi.org/10.1182/blood.V126.23.4260.4260

Published: 2015

Journal Articles

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Andreas R. Thomsen, MD, Claudius Klein, Christine Aldrian, Martin Kortuem, MD, Marie Follo, PhD, Julia Schüler, DVM, PhD, Justus Duyster, MD PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 1822.

https://doi.org/10.1182/blood.V126.23.1822.1822

Published: 2015

Journal Articles

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Maike Nickelsen, MD, Carmen Canals, Sr., Charalampia Kyriakou, MD, PhD, Norbert Schmitz, MD, PhD, Agnes Buzyn, MD, Monika Engelhardt, MD, PhD, Bertram Glass, MD, PhD, Eulogio Conde, MD, Armando Lopez-Guillermo, MD, Gerard Socie, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 974.

https://doi.org/10.1182/blood.V112.11.974.974

Published: 2008

Journal Articles

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Maike Nickelsen, MD, Carmen Canals, Sr., MD, Norbert Schmitz, MD, PhD, Charalampia Kyriakou, MD, PhD, Monika Engelhardt, MD, PhD, Thomas Relander, MD, Werner Linkesch, MD, PhD, Vladimir Koza, MD, Giovanna Meloni, MD, Armando Lopez-Guillermo, MD, Karel Indrac, MD, Dolores Caballero, MD, Hannes Wandt, MD, PhD, Niklas Theorin, MD, Bertram Glass, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 774.

https://doi.org/10.1182/blood.V112.11.774.774

Published: 2008

NARROW

PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

The APC/C Coactivator Cdh1 Controls Self-Renewal and Differentiation of Human and Murine HSPCs

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only